Surgery

TransEnterix Announces Maastricht University Medical Center+ in the Netherlands to Initiate Program with the Senhance Surgical System

Retrieved on: 
Monday, July 27, 2020
General Health, Surgery, Medical devices, Hospitals, Health, South Limburg, Maastricht UMC+, Maastricht, University Medical Center, UMC, Geography of the Netherlands, TransEnterix, Maastricht UMC+

This new program is a major milestone for the growth of Senhance, said Anthony Fernando, president and chief executive officer at TransEnterix.

Key Points: 
  • This new program is a major milestone for the growth of Senhance, said Anthony Fernando, president and chief executive officer at TransEnterix.
  • Maastricht UMC+ will be the first hospital utilizing Senhance in a comprehensive multi-specialty program led by pediatric surgery and the Woman-Mother-Child Center.
  • We are pleased to partner with a leading medical center like Maastricht UMC+, and this program highlights the continued momentum we are seeing in areas such as the Netherlands and Germany.
  • This press release includes statements relating to the Senhance System and the Maastricht University Medical Center+ initiating a program with the Senhance System.

Global Orthopedic Prosthetics Market Analysis Highlights the Impact of COVID-19 2020-2024 | Use of Technically Advanced Orthopedic Prosthetics to Boost Market Growth | Technavio

Retrieved on: 
Monday, July 27, 2020
Surgery, Health, Other Health, Biological engineering, Biomedical engineering, Prosthesis, Coronavirus disease, Health, Medicine

The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.

Key Points: 
  • The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.
  • Technavios in-depth research has all your needs covered as our research reports include all foreseeable market scenarios, including pre- & post-COVID-19 analysis.
  • Download a Free Sample Report on COVID-19 Impacts
    What was the size of the orthopedic prosthetics market in 2019?
  • The increasing use of technically advanced orthopedic prosthetics has been instrumental in driving the growth of the market.

Global Veterinary Surgical Devices Market Analysis Highlights the Impact of COVID-19 2020-2024| Rising Number of Surgical Procedures to Boost Market Growth | Technavio

Retrieved on: 
Monday, July 27, 2020
Health, Veterinary, Medical devices, Surgery

The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.

Key Points: 
  • The report offers an up-to-date analysis regarding the current market scenario, latest trends and drivers, and the overall market environment.
  • The rising number of surgical procedures has been instrumental in driving the growth of the market.
  • The rising number of surgical procedures has been instrumental in driving the growth of the market.
  • Veterinary Surgical Devices Market 2020-2024: Segmentation
    Veterinary Surgical Devices Market is segmented as below:

Dominick P. Artuso, MD is recognized by Continental Who's Who

Retrieved on: 
Saturday, July 25, 2020
Medical specialties, Surgery, Clinical medicine, Surgical specialties, Bariatric surgery, Digestive system surgery, American Board of Surgery, General surgery, New York Medical College

Board-Certified Surgeon, Dr. Artuso has garnered 30 years of professional experience demonstrating the highest level of professionalism and integrity.

Key Points: 
  • Board-Certified Surgeon, Dr. Artuso has garnered 30 years of professional experience demonstrating the highest level of professionalism and integrity.
  • He offers a vast repertoire of expertise in bariatric surgery and revisions, as well as nutritional counseling.
  • Following this, he relocated to New York and completed a
    general surgery residency at New York Medical College - Westchester City Medical Center.
  • Dr. Artuso is dual certified in General Surgery and Bariatric Surgery by the American Board of Surgery.

Heron Therapeutics Receives Positive CHMP Opinion for ZYNRELEF™ (HTX-011) for the Management of Postoperative Pain

Retrieved on: 
Friday, July 24, 2020
Pain, Perception, Acute pain, Palliative care, Morphine, Opioid, Bupivacaine, Surgery, Postoperative nausea and vomiting, Pain management in children

The CHMP's positive opinion is based on the results of Heron's two Phase 3 studies of ZYNRELEF.

Key Points: 
  • The CHMP's positive opinion is based on the results of Heron's two Phase 3 studies of ZYNRELEF.
  • ZYNRELEF demonstrated significantly reduced pain and opioid use through 72 hours compared to bupivacaine solution, the current standard-of-care anesthetic for postoperative pain control.
  • ZYNRELEF significantly reduced pain intensity through 72 hours postsurgery, significantly reduced the use of opioid medications following surgery and significantly increased the proportion of patients who required no postoperative opioid medications.
  • The CHMP recommended that ZYNRELEF be indicated for treatment of somatic postoperative pain from small- to medium-sized surgical wounds in adults.

Global Restenosis Pipeline Research Monitor, 2020 - ResearchAndMarkets.com

Retrieved on: 
Friday, July 24, 2020
Biotechnology, Pharmaceutical, Health, Cardiology, Restenosis, Surgery, Drug pipeline, Pipeline

The "Restenosis Pipeline Research Monitor, 2020 - Drugs, Companies, Clinical Trials, R&D Pipeline Updates, Status and Outlook" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Restenosis Pipeline Research Monitor, 2020 - Drugs, Companies, Clinical Trials, R&D Pipeline Updates, Status and Outlook" report has been added to ResearchAndMarkets.com's offering.
  • The Restenosis pipeline Research Monitor, 2020 report is an analytical research study on the progress achieved by pipeline companies during the year along with its historical development, current status, and outlook.
  • This Restenosis pipeline review explores high-potential early to late-stage pipeline projects with a continued focus on new insights, accelerated processes, and pipeline progression.
  • The competitive intelligence report on Restenosis presents detailed insights into therapeutic drug pipeline development, industry news, deals, and analysis across the length and breadth of the Restenosis pipeline.

Venock Inc. Paves the Way for First Universal Large Bore Vascular Closure System Designed for Veins and Arteries

Retrieved on: 
Friday, July 24, 2020
Biotechnology, Surgery, Medical devices, Health, Cardiology, Cardiovascular system, Circulatory system, Angiology, Cardiovascular physiology, Medical specialties, Blood vessel, Vein, Artery, Vascular access, Interventional radiology, Angioplasty

All such therapies are facing growing demand and require large bore vascular access, with sites that can be as big as the diameter of the vessel itself.

Key Points: 
  • All such therapies are facing growing demand and require large bore vascular access, with sites that can be as big as the diameter of the vessel itself.
  • We invested a great deal of effort to expand our large bore venous closure technology to include closure of large bore arterial perforations.
  • Venock is developing the first universal large bore closure device for veins and arteries.
  • Its Vascular Closure Device is designed to close very large perforations that can be as big as the diameter of the vein or the artery.

Aroa Biosurgery Commences Trading on the ASX

Retrieved on: 
Friday, July 24, 2020
Biotechnology, Health, Surgery, Medical devices, Australian Securities Exchange, Economy of New South Wales, ASX, Economy of Australia

Soft tissue regeneration company Aroa Biosurgery Limited (ASX:ARX, Aroa or the Company) commences trading on the Australian Securities Exchange (ASX) today following the completion of an initial public offering (IPO) that raised $45m from investors.

Key Points: 
  • Soft tissue regeneration company Aroa Biosurgery Limited (ASX:ARX, Aroa or the Company) commences trading on the Australian Securities Exchange (ASX) today following the completion of an initial public offering (IPO) that raised $45m from investors.
  • Aroa is focused on improving the rate and quality of healing in complex wounds and soft tissue reconstruction.
  • From more than 10 years of research and development Aroa has developed Endoform, a proprietary soft tissue regeneration technology platform.
  • Founded in 2008, Aroa is headquartered in Auckland, New Zealand and is listed on the Australian Securities Exchange (ASX:ARX).

Revance Completes Previously Announced Acquisition of HintMD and its Proprietary Fintech Platform for Aesthetic Practices

Retrieved on: 
Thursday, July 23, 2020
Biotechnology, Practice Management, Online Retail, Technology, Professional services, Health, Pharmaceutical, Other Technology, Retail, Surgery, Finance, Financial technology

The acquisition of HintMD augments Revances strong aesthetics product offering, enabling us to transform both the practice and patient experience with an innovative fintech platform, said Mark Foley, President and Chief Executive Officer of Revance.

Key Points: 
  • The acquisition of HintMD augments Revances strong aesthetics product offering, enabling us to transform both the practice and patient experience with an innovative fintech platform, said Mark Foley, President and Chief Executive Officer of Revance.
  • The acquisition of HintMD provides Revance with access to an estimated $500-plus million market opportunity in U.S. aesthetic practice payment services through its unique, integrated digital services platform.
  • In connection with the acquisition of HintMD, Revance granted special inducement equity awards under the Revance 2014 Inducement Plan to retain certain former HintMD employees (75 in total) as employees of Revance.
  • Revance Therapeutics and the Revance logo are registered trademarks of Revance Therapeutics, Inc.
    Resilient Hyaluronic Acid and RHA are trademarks of TEOXANE SA.

Health Discovery Corporation Files Infringement Suit Against Intel Corporation

Retrieved on: 
Thursday, July 23, 2020
Legal, Clinical trials, Cardiology, Surgery, Biotechnology, Finance, Alternative medicine, Health, Research, Professional services, Nanotechnology, Science, Veterinary, Software, FDA, Hardware, Diabetes, Radiology, Data management, Pharmaceutical, Technology, Oncology, Medical devices, Infectious diseases, Genetics, Computing, Companies, Intel, Forward-looking statement, Discovery, Economy of the United States

Health Discovery Corporation (Health Discovery, HDC or the Company), an intellectual property development company with an intellectual property portfolio using patent protected advanced mathematical techniques, announced today that it has filed an infringement lawsuit against Intel Corporation (Intel) (NASDAQ: INTC).

Key Points: 
  • Health Discovery Corporation (Health Discovery, HDC or the Company), an intellectual property development company with an intellectual property portfolio using patent protected advanced mathematical techniques, announced today that it has filed an infringement lawsuit against Intel Corporation (Intel) (NASDAQ: INTC).
  • This infringement suit pertains to Health Discoverys Support Vector Machine-Recursive Feature Elimination methods (SVM-RFE) patents.
  • Health Discovery operates primarily in the field of molecular diagnostics where such tools are critical to scientific discovery.
  • All forward-looking statements and cautionary statements included in this document are made as of the date hereof based on information available to Health Discovery Corporation as of the date hereof, and Health Discovery Corporation assumes no obligation to update any forward-looking statement or cautionary statement.